CERC CERECOR INC

Avalo Therapeutics to Present at Upcoming Investor Conferences

Avalo Therapeutics to Present at Upcoming Investor Conferences

WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences:

Stifel 2024 Healthcare Conference, New York

Monday, November 18, 2024 at 3:35 PM ET

Piper Sandler 36th Annual Healthcare Conference, New York

Wednesday, December 5, 2024 at 11:00 AM ET

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at . The archived webcasts will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional drug candidates, which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). For more information about Avalo, please visit .

About AVTX-009 

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.

For media and investor inquiries

Christopher Sullivan, CFO

Avalo Therapeutics, Inc.

 

410-803-6793

or

Meru Advisors

Lauren Glaser

 



EN
11/11/2024

Underlying

CERCCERECOR INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERECOR INC

 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. “We are thrilled to welcome Jennifer to ...

January 2, 2025 1 EN
 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Ex...

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 millionCash runway expected into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that it has received $69.4 million in gross proceeds from the full ex...

November 12, 2024 1 EN
 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Therapeutics to Present at Upcoming Investor Conferences

Avalo Therapeutics to Present at Upcoming Investor Conferences WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences: Stifel 2024 Healthcare Conference, New YorkMonday, November 18, 2024 at 3:35 PM ET Piper Sandler 36th Annual Healthcare Conference, New YorkWednesday, December 5, 2024 at 11:00 AM ET Live we...

November 11, 2024 1 EN
 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Reports Third Quarter 2024 Financial Results and Recent Business...

Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026Cash position of approximately $82 million as of September 30, 2024 with subsequent receipt of approximately $58 million of warrant exercise proceeds in 4Q 2024, provides expected runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatmen...

November 7, 2024 1 EN
 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009...

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to placeboTopline data expected in 2026 WAYNE, Pa. and ROCKVILLE, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that the first patient has been dosed in the Company’s Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS). AVTX-009 is a humanized monoclonal antibody ...

October 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch